0
Post your comment
GMP
Generic medicines manufacturers must comply with the strict rules of good manufacturing practice (GMP). This ensures that all medicines—generic and originator alike—are produced consistently and controlled to stringent standards of quality in accordance with current legislation.
ICH requirements
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has the following requirements in order to assure the quality of generic drugs:
Legal supply chain
The EU directive 2001/83/EC art 51.3 means that all production batches of generic drugs have to be officially released and records of this kept so that the competent authority can review them.
It is therefore essential that generics manufacturers maintain a relationship with active pharmaceutical ingredient (API) manufacturers in order to maintain integrity. This involves maintaining contacts and carrying out visits/audits. This is the only way to guarantee continuous quality assurance and the safety of patients.
Quality is maintained in the legal supply chain by:
There is also an EC proposal to have a written declaration by the exporting country attesting the ‘equivalence of standards’ to those of the EU. This reinforces the degree of supervision and levels the playing field between EU and non-EU API manufacturers.
Related articles
A sustainable generics industry in the EU
The role of generic drugs in the EU
Generic drugs – registration, quality, value and sustainability
Registration procedures for generic drugs in the EU
Generic applications in the EU, patents and exclusivity
Source: EGA, ICH, Official Journal of the European Union
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Sign up today for the weekly briefing on the latest developments in generic and biosimilar medicines!
Post your comment